MS Forum® VIII: Advancing MS Care in the Pandemic Era

MS Forum® VIII: Advancing MS Care in the Pandemic Era

Course Chair
Patricia K. Coyle, MD, FAAN, FANA

Patricia K. Coyle, MD, FAAN, FANA

Professor and Vice Chair (Clinical Affairs)

Department of Neurology

Director

Stony Brook MS Comprehensive Care Center

Stony Brook University

Stony Brook, NY


Faculty
Bruce A. Cohen, MD, FAAN, FANA, FACP

Bruce A. Cohen, MD, FAAN, FANA, FACP

Professor of Neurology

Northwestern University

Feinberg School of Medicine

Director

Northwestern Comprehensive Multiple Sclerosis Program

Chicago, IL


Stephen Krieger, MD, FAAN

Stephen Krieger, MD, FAAN

Professor of Neurology

The Corinne Goldsmith Dickinson Center for MS

Icahn School of Medicine at Mount Sinai

New York, NY


Clyde E. Markowitz, MD

Clyde E. Markowitz, MD

Associate Professor of Neurology

Emeritus Director, Multiple Sclerosis Center

Perelman School of Medicine

University of Pennsylvania

Philadelphia, PA


Contact Us

Vindico Medical Education
6900 Grove Road
Thorofare, NJ 08086

Email Us




These continuing education activities are provided by
Vindico Medical Education

Endorsed by
CMSC

These activities are supported by educational grants from EMD Serono, Inc. and Genentech, a member of the Roche Group.

Three-Part CE Webinar Series

Register for each CME/CNE webinar below. Attend all 3 to earn up to 6.0 CME/CNE credits!


Session 1: Novel Advances and the Optimization of MS Treatments
Saturday, August 13, 2022

11:00 am – 1:00 pm ET

Topics

  • The Year in Review: Novel Advances in MS
  • Vaccines in MS: Immunization Protocols in Patients with MS
  • Clinical Cases
  • Differentiating DMTs to Optimize Treatment Individualization
  • Focus on BTK Inhibitors: Clinical Updates
  • LIVE Question & Answer
motionmailapp.com
Register Now!

Session 2: Biomarkers, Imaging, and Gender-Based Issues in MS
Saturday, August 20, 2022

11:00 am – 1:00 pm ET

Topics

  • Updates in Imaging and Biomarkers
  • Gender-Based Issues in MS
  • Clinical Case
  • TED Talks in MS: Where We Are, Where We’re Headed
  • Panel Discussion
  • LIVE Question & Answer
motionmailapp.com
Register Now!

Session 3: Updates on Progressive MS, the Patient Perspective, and MS Management in the COVID-19 Era
Saturday, September 17, 2022

11:00 am – 1:00 pm ET

Topics

  • Patient Perspectives in MS
  • Advances in Progressive MS: Optimizing Patient Recognition and Treatment
  • Clinical Cases
  • Effect of Environmental Factors and Comorbidities: Impact on MS Care
  • Rapid-Fire Controversies in MS
  • LIVE Question & Answer
motionmailapp.com
Register Now!

Series Overview

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. The live, virtual “MS Forum® VIII: Advancing MS Care in the Pandemic Era” is a 3-part, multi-accredited webinar series that aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with MS. This session will incorporate didactic presentations and case presentations covering the effect of environmental factors and comorbidities in patients with MS, advances in progressive MS, as well as rapid-fire controversies in MS. This session will also feature the patient perspective, with video segments of a patient with MS addressing common concerns and the role of shared decision-making.

Target Audience

The intended audience for this activity is neurologists, neurology nurses, neurology advance practice providers, and other health care professionals involved in the management of patients with MS.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians
  • Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging disease-modifying therapies (DMTs) for the treatment of patients with MS.
  • Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
  • Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  • Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.
  • Utilize strategies for the early identification of patients with RRMS or progressive MS to facilitate timely intervention.
  • Determine treatment for patients with RRMS or progressive MS based on evidence-based recommendations.
  • Incorporate knowledge of the benefit/risk profiles of disease modifying therapies (DMTs), including COVID-19-related safety issues, when making decisions about early treatment for patients with MS.
  • Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.
Nurses
  • Assess the most recent clinical and/or real-world evidence regarding the safety and efficacy of current and emerging disease-modifying therapies (DMTs) for the treatment of patients with MS.
  • Evaluate the burden of comorbidities in patients with MS and their impact on quality of life.
  • Identify clinical trends and controversies in MS that may have implications on clinical decision-making.
  • Review data regarding the impact of DMTs on overall immune response to vaccines (including non-COVID-19 vaccines) into clinical decision-making.
  • Examine the role of shared decision-making and strategies to improve patient-provider communication regarding the disease state and selection of optimal DMTs in alignment with patient preferences.